|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01548 GENSCRIPT BIO
Nominal 
11.230 +0.140 (+1.262%) | 2025/12 - Final USD(K$) | %Chg (Compare to Final) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | |
| Turnover | 959,526 | 61.404% | 594,486 | 839,529 | 625,698 | 490,096 |
| Cost of Sales | (406,322) | 26.046% | (322,361) | (429,976) | (321,615) | (207,578) |
| Gross Profit | 553,204 | 103.290% | 272,125 | 409,553 | 304,083 | 282,518 |
| 2025/12 - Final USD(K$) | %Chg (Compare to Final) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (426,901) | 143.041% | (175,650) | 27,020 | 6,140 | (140,864) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (320,378) | 719.968% | (39,072) | (1,384) | (27) | 0 | |
| Profit / (Loss) before Taxation | (470,533) | 175.493% | (170,797) | (350,979) | (431,690) | (517,363) | |
| Taxation | (61,871) | 1978.300% | (2,977) | (4,142) | 3,719 | (964) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | 3,029,061 | -- | -- | -- | |
| Non-controlling Interests | (426) | -- | 106,590 | 259,644 | 201,120 | 159,615 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (532,830) | -- | 2,961,877 | (95,477) | (226,851) | (358,712) | |
| 2025/12 - Final USD(K$) | %Chg (Compare to Final) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | |
| Net Finance Costs / (Income) | 17,294 | 115.314% | 8,032 | 27,510 | 13,269 | (407) |
| Depreciation & Amortisation | 74,039 | 20.314% | 61,538 | 74,046 | 64,248 | 47,779 |
| Directors' Emoluments | -- | -- | 3,194 | 2,479 | 3,042 | 2,860 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified (Modified Report) |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -24.580 | -- | 139.630 | -4.530 | -10.820 | -17.670 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.150 | -- | 0.036 | (0.136) | (0.057) | (0.067) |
| NBV per share ($) | 1.811 | -- | 2.016 | 0.655 | 0.478 | 0.498 |
| Remarks: | Real time quote last updated: 16/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | USD -532,830 |
| %Change | -- |
| EPS / (LPS) | USD -0.246 |
| NBV Per Share ($) | USD 1.811 |